| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1995;59:132-136
© 1995 The Society of Thoracic Surgeons
Departments of Surgery and Radiology, The University of Iowa College of Medicine, Iowa City, Iowa, and Miles Inc, West Haven, Connecticut, and Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, and Department of Surgery, Deborah Heart and Lung Center, Brown Mills, New Jersey, and Departments of Radiology and Surgery, The University of Chicago, Chicago, Illinois, and Department of Cardiovascular Diseases and Section of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota
Accepted for publication July 16, 1994.
Two hundred sixteen patients undergoing coronary artery bypass graft procedures were randomized to receive either high-dose aprotinin or placebo. Clinically important postoperative renal insufficiency was infrequent, with a single patient (0.9%) from each group requiring dialysis. Although increases in the serum creatinine level occurred postoperatively in more patients who received aprotinin (20/108) than in those given placebo (13/108), the difference between the two groups was not statistically significant (p = 0.186), and the increases were generally small and transient. Likewise, there was no difference between the groups in terms of the incidence of abnormal serum electrolyte levels, blood urea nitrogen levels, or urinalysis findings, or in the frequency of abnormal creatinine clearance rates. Under the conditions described, aprotinin use does not appear to be associated with a significant risk of serious renal toxicity.
This article has been cited by other articles:
|
|
 |
|
  G. Lindvall, U. Sartipy, T. Ivert, and J. van der Linden Aprotinin is not associated with postoperative renal impairment after primary coronary surgery. Ann. Thorac. Surg., July 1, 2008; 86(1): 13 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pagano, N. J. Howell, N. Freemantle, D. Cunningham, R. S. Bonser, T. R. Graham, J. Mascaro, S. J. Rooney, I. C. Wilson, R. Cramb, et al. Bleeding in cardiac surgery: The use of aprotinin does not affect survival J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 495 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Van der Linden, J.-F. Hardy, A. Daper, A. Trenchant, and S. G. De Hert Cardiac surgery with cardiopulmonary bypass: does aprotinin affect outcome? Br. J. Anaesth., November 1, 2007; 99(5): 646 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. McEvoy, S. T. Reeves, J. G. Reves, and F. G. Spinale Aprotinin in Cardiac Surgery: A Review of Conventional and Novel Mechanisms of Action Anesth. Analg., October 1, 2007; 105(4): 949 - 962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al. Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Royston, J. H. Levy, J. Fitch, W. Dietrich, S. C. Body, J. M. Murkin, B. D. Spiess, and A. Nadel Full-Dose Aprotinin Use in Coronary Artery Bypass Graft Surgery: An Analysis of Perioperative Pharmacotherapy and Patient Outcomes Anesth. Analg., November 1, 2006; 103(5): 1082 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Abu-Omar and C. Ratnatunga Cardiopulmonary Bypass and Renal Injury Perfusion, July 1, 2006; 21(4): 209 - 213. [Abstract] [PDF]
|
|
|
|
|
|
T. Shiga, Z. Wajima, T. Inoue, and A. Sakamoto Aprotinin in Major Orthopedic Surgery: A Systematic Review of Randomized Controlled Trials Anesth. Analg., December 1, 2005; 101(6): 1602 - 1607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Kincaid, D. A. Ashburn, J. R. Hoyle, M. G. Reichert, J. W. Hammon, and N. D. Kon Does the Combination of Aprotinin and Angiotensin-Converting Enzyme Inhibitor Cause Renal Failure After Cardiac Surgery? Ann. Thorac. Surg., October 1, 2005; 80(4): 1388 - 1393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kher, K. K. Meldrum, K. L. Hile, M. Wang, B. M. Tsai, M. W. Turrentine, J. W. Brown, and D. R. Meldrum Aprotinin improves kidney function and decreases tubular cell apoptosis and proapoptotic signaling after renal ischemia-reperfusion J. Thorac. Cardiovasc. Surg., September 1, 2005; 130(3): 662 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Mahdy and N. R. Webster Perioperative systemic haemostatic agents Br. J. Anaesth., December 1, 2004; 93(6): 842 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Taggart, V. Djapardy, M. Naik, and A. Davies A randomized trial of aprotinin (Trasylol) on blood loss, blood product requirement, and myocardial injury in total arterial grafting J. Thorac. Cardiovasc. Surg., October 1, 2003; 126(4): 1087 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Grayson, M. Khater, M. Jackson, and M. A. Fox Valvular heart operation is an independent risk factor for acute renal failure Ann. Thorac. Surg., June 1, 2003; 75(6): 1829 - 1835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Vijay and J. P. Gold Late Complications of Cardiac Surgery Card. Surg. Adult, January 1, 2003; 2(2003): 521 - 537. [Full Text]
|
|
|
|
|
|
C. J. O’Connor, D. V. Brown, M. Avramov, S. Barnes, H. N. O’Connor, and K. J. Tuman The Impact of Renal Dysfunction on Aprotinin Pharmacokinetics During Cardiopulmonary Bypass Anesth. Analg., November 1, 1999; 89(5): 1101 - 1101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Munoz, N. J. O. Birkmeyer, J. D. Birkmeyer, G. T. O'Connor, and L. J. Dacey Is {epsilon}-Aminocaproic Acid as Effective as Aprotinin in Reducing Bleeding With Cardiac Surgery? : A Meta-Analysis Circulation, January 12, 1999; 99(1): 81 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Rich The efficacy and safety of aprotinin use in cardiac surgery Ann. Thorac. Surg., November 1, 1998; 66(90050): S6 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Lemmer Jr, E. W. Dilling, J. R. Morton, J. B. Rich, F. Robicsek, D. L. Bricker, C. B. Hantler, J. G. Copeland III, J. L. Ochsner, P. O. Daily, et al. Aprotinin for Primary Coronary Artery Bypass Grafting: A Multicenter Trial of Three Dose Regimens Ann. Thorac. Surg., December 1, 1996; 62(6): 1659 - 1668. [Abstract] [Full Text]
|
|
|
|
|
|
M. N. D'Ambra, C. W. Akins, E. H. Blackstone, S. L. Bonney, L. H. Cohn, D. M. Cosgrove, J. H. Levy, K. E. Lynch, and R. Maddi APROTININ IN PRIMARY VALVE REPLACEMENT AND RECONSTRUCTION: A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL J. Thorac. Cardiovasc. Surg., October 1, 1996; 112(4): 1081 - 1089. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Moulton, L. L. Creswell, M. E. Mackey, J. L. Cox, and M. Rosenbloom REEXPLORATION FOR BLEEDING IS A RISK FACTOR FOR ADVERSE OUTCOMES AFTER CARDIAC OPERATIONS J. Thorac. Cardiovasc. Surg., May 1, 1996; 111(5): 1037 - 1046. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
